First Trust NYSE Arca Biotechnology Index Fund (FBT) Holdings
FBT holdings summary
as of Oct 25, 2026- Holdings
- 30 positions listed
- Top 10 weight
- 35.6% of net assets
- Effective holdings
- 30 equal-weight equivalent
- Largest holding
- HALO 3.66% Halozyme Therapeutics, Inc.
- Annual turnover
- 30.0% of the portfolio traded
All FBT holdings
| # | Name | ||||||
|---|---|---|---|---|---|---|---|
| 1 | HALO | Halozyme Therapeutics, Inc. | Healthcare | 3.66% | $108.9M | $13.83B | 35.6 |
| 2 | EXEL | Exelixis, Inc. | Healthcare | 3.65% | $108.8M | $15.42B | 19.6 |
| 3 | GMAB | Genmab A/S | Healthcare | 3.62% | $107.6M | $22.75B | 29.1 |
| 4 | ONC | BeiGene, Ltd. | Healthcare | 3.60% | $107.1M | $41.99B | 66.0 |
| 5 | AMGN | Amgen Inc. | Healthcare | 3.60% | $107.1M | $233.82B | 26.9 |
| 6 | BIIB | Biogen Inc. | Healthcare | 3.52% | $104.8M | $34.37B | 41.3 |
| 7 | ALKS | Alkermes plc | Healthcare | 3.50% | $104.2M | $6.92B | 108.5 |
| 8 | VRTX | Vertex Pharmaceuticals Incorporated | Healthcare | 3.50% | $104.1M | $126.66B | 28.9 |
| 9 | ARGX | argenx SE | Healthcare | 3.49% | $104.0M | $51.51B | 31.2 |
| 10 | REGN | Regeneron Pharmaceuticals, Inc. | Healthcare | 3.48% | $103.6M | $81.41B | 19.6 |
| 11 | UTHR | United Therapeutics Corporation | Healthcare | 3.43% | $102.1M | $22.87B | 19.1 |
| 12 | BMRN | BioMarin Pharmaceutical Inc. | Healthcare | 3.39% | $100.8M | $10.58B | 147.8 |
| 13 | NBIX | Neurocrine Biosciences, Inc. | Healthcare | 3.38% | $100.7M | $13.79B | 19.9 |
| 14 | INCY | Incyte Corporation | Healthcare | 3.38% | $100.7M | $22.92B | 14.4 |
| 15 | VCYT | Veracyte, Inc. | Healthcare | 3.35% | $99.6M | $3.47B | 30.8 |
| 16 | GILD | Gilead Sciences, Inc. | Healthcare | 3.31% | $98.6M | $193.67B | — |
| 17 | ADMA | ADMA Biologics, Inc. | Healthcare | 3.28% | $97.7M | $2.39B | 15.3 |
| 18 | ALNY | Alnylam Pharmaceuticals, Inc. | Healthcare | 3.28% | $97.5M | $31.02B | 39.1 |
| 19 | NTRA | Natera, Inc. | Healthcare | 3.27% | $97.4M | $56.71B | — |
| 20 | TECH | Bio-Techne Corporation | Healthcare | 3.19% | $94.9M | $11.38B | 62.6 |
| 21 | RGEN | Repligen Corporation | Healthcare | 3.17% | $94.5M | $11.14B | 240.3 |
| 22 | TARS | Tarsus Pharmaceuticals, Inc. | Healthcare | 3.15% | $93.8M | $3.19B | — |
| 23 | BRKR | Bruker Corporation | Healthcare | 3.15% | $93.7M | $8.35B | — |
| 24 | ILMN | Illumina, Inc. | Healthcare | 3.15% | $93.7M | $39.64B | 49.0 |
| 25 | NEO | NeoGenomics, Inc. | Healthcare | 3.10% | $92.3M | $2.14B | — |
| 26 | BNTX | BioNTech SE | Healthcare | 3.09% | $92.0M | $22.03B | — |
| 27 | TGTX | TG Therapeutics, Inc. | Healthcare | 3.07% | $91.5M | $8.26B | 19.6 |
| 28 | AXSM | Axsome Therapeutics, Inc. | Healthcare | 3.00% | $89.2M | $8.23B | — |
| 29 | MDGL | Madrigal Pharmaceuticals, Inc. | Healthcare | 2.99% | $88.9M | $10.39B | — |
| 30 | CORT | Corcept Therapeutics Incorporated | Healthcare | 2.79% | $83.1M | $11.91B | 244.8 |
Weights as a percentage of net assets. Value held = weight × net assets ($2.98B). Market cap and P/E from each company's latest fundamentals (U.S.-listed stocks).
FBT sector breakdown
Sum of the weights of the holdings in each sector.
FBT top industries
FBT overlap with other ETFs
| ETF | Fund | Overlap | Shared holdings | Expense ratio |
|---|---|---|---|---|
| DIA | SPDR Dow Jones Industrial Average ETF | 3.6% | 1 of 30 | 0.16% |
| QQQ | Invesco QQQ ETF | 3.0% | 5 of 101 | 0.17% |
| VTI | Vanguard Total Stock Market ETF | 1.3% | 26 of 2,941 | 0.03% |
| SPY | SPDR S&P 500 ETF | 1.1% | 8 of 502 | 0.09% |
| IWM | iShares Russell 2000 ETF | 0.9% | 6 of 1,962 | 0.19% |
| VXUS | Vanguard Total International Stock ETF | 0.1% | 1 of 8,035 | 0.05% |
Overlap = sum over shared holdings of the smaller of the two weights. 100% means identical portfolios.
About the FBT portfolio
First Trust NYSE Arca Biotechnology Index Fund holds 30 positions. The ten largest make up 35.6% of the fund, so it behaves like a portfolio of about 30 equally weighted stocks. The biggest positions are Halozyme Therapeutics, Inc. (3.66%), Exelixis, Inc. (3.65%), Genmab A/S (3.62%), BeiGene, Ltd. (3.60%), Amgen Inc. (3.60%).
By sector, Healthcare is 99.5%. Holdings data is from the fund's latest portfolio as reported by EODHD on October 25, 2026; positions change as the fund rebalances.
Related: FBT chart, FBT performance, FBT valuation, FBT overview.
FBT holdings FAQ
How many holdings does FBT have?
FBT holds 30 positions as of October 25, 2026.
What are the top 10 holdings of FBT?
The ten largest holdings are Halozyme Therapeutics, Inc. (3.66%), Exelixis, Inc. (3.65%), Genmab A/S (3.62%), BeiGene, Ltd. (3.60%), Amgen Inc. (3.60%), Biogen Inc. (3.52%), Alkermes plc (3.50%), Vertex Pharmaceuticals Incorporated (3.50%), argenx SE (3.49%), Regeneron Pharmaceuticals, Inc. (3.48%). Together they are 35.6% of the fund.
What percentage of FBT is Halozyme Therapeutics, Inc.?
Halozyme Therapeutics, Inc. is the largest holding at 3.66% of net assets, about $108.9M of the fund's $2.98B.
How concentrated is FBT?
The top 10 holdings are 35.6% of the fund. By the effective number of holdings (1 divided by the sum of squared weights) FBT behaves like a portfolio of about 30 equally weighted stocks.